6 first-half 2024 oncology data readouts to watch

On February 16, the FDA approved the first one-time cell therapy for a solid tumor and the first tumor-infiltrating lymphocytes therapy. It was a decision one expert said “will unlock more innovation in the industry” and benefit cancer patients.

There has, in fact, been so much innovation in cancer treatment during the past decade that the FDA moved away from the “gold standard” of overall survival in favor of progression-free survival when making approval decisions, though that could now be changing.